Novo-Nordisk stock heads into the open after a 3.1% drop
Published on 09/10/2026 at 07:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo-Nordisk stock closed at USD 45.16 on its US listing on September 8, 2026, down 3.09% from the prior close of USD 46.63 per New York quote data at 4:00 p.m. EDT. The move left the shares lagging a roughly 0.6% decline in the S&P 500 over the same session, underscoring renewed selling pressure in large-cap healthcare names.
September 8, 2026 in numbers
Novo-Nordisk A/S (ISIN DK0062498333) saw its American depositary receipts trade between roughly USD 44.90 and USD 45.80 on September 8, 2026, before settling at USD 45.16 in regular US trading, a decline of 3.09% on the day against the prior close of USD 46.63. Per US market data, the closing level left the stock closer to its 52-week low near USD 35.12 than to the 52-week high around USD 64.16, highlighting a significant retreat from peak valuations over the past year. In comparison, the S&P 500 finished the September 8, 2026 session about 0.6% lower, so Novo-Nordisk underperformed the broader US benchmark by more than 2 percentage points.
As Ad-Hoc-News reported on September 8, 2026, the decline came as Novo-Nordisk continued to advance a share repurchase program of up to DKK 15 billion, with recent transactions adding to the total B shares bought back under the current authorization. According to StockTitan, the company disclosed that by September 4, 2026 it had repurchased more than 32 million B shares since February 4, 2026 for a total transaction value of around DKK 9.0 billion, underscoring managements ongoing capital-return focus even as the stock trades below its recent highs.
Today’s drivers and events
Today, September 10, 2026, Novo-Nordisk stock heads into the US open without a scheduled earnings release, but investors remain attentive to the progression of the company’s large-scale buyback program and broader market risk sentiment. As Saxo noted on September 9, 2026, the S&P 500 and Nasdaq 100 both slipped in the latest session amid concerns over oil prices and geopolitical tensions, factors that could continue to influence risk appetite across global equities today. In the healthcare and pharmaceutical space, sentiment may also be shaped by recent clinical and regulatory news affecting large peers, as highlighted by coverage from BioSpace, which detailed setbacks in cardiovascular and neurological trial programs at other companies. Against this backdrop, Novo-Nordisk shares may react today to any further updates on its own research pipeline, capital-allocation actions or sector-wide news as trading resumes.
